Cognition Therapeutics, Inc., a South Side-based clinical-stage neuroscience company, has filed for an initial public offering, submitted June 19.
The company is looking to raise up to $50 million through the IPO. It has applied to list its common stock on the Nasdaq under the ticker symbol CGTX.
Cognition Therapeutics is working to treat Alzheimer’s disease and other central nervous system diseases by working to develop medication to restore cellular damage responses.
According to their SEC filing, Alzheimer’s affects about 6.2 million people in the U.S., a number that’s “expected to more than double by 2050.”
Emma Skidmore: eskidmore@post-gazette.com





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.